China’s early-stage investor Morningside Venture Capital has led a $40-million Series A investment in gene therapy company Apic Bio, which is developing treatment options for patients with rare genetic diseases.
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in
